Individual CD34(+)CD38(low)CD19(-)CD10(-) progenitor cells from human cord blood generate B lymphocytes and granulocytes

Identification of human hematopoietic stem cells and analysis of molecular mechanisms regulating their function require biological assays that permit differentiation in all hematopoietic lineages simultaneously. In this study, we established conditions that permit the joint expression of the B-lymphoid and myeloid potential from cord blood-derived CD34(+)CD38(low)CD19(-)/CD10(-) primitive progenitors that lack B-specific markers and transcripts. When cocultured during 6 weeks with the murine stromal cells MS-5 in the absence of exogenous human cytokines, CD34(+)CD38(low)-CD19(-)CD10(-) cells generated a high number of CD19(+) B cells. Virtually all of these cells expressed a CD34(-)CD10(+)-CD19(+)clgM(-) phenotype of late pro-B cells and transcripts of Pax-5, lambda-like, and mu chain were detected. We further show that 7% of CD34(+)CD38(low)CD19(-) cells from cord blood, when grown individually with MS-5 cells, generated both CD19(+) and CD11b(+) cells after 6 weeks, Efficient B-cell differentiation was also observed in vivo after transplantation of human cord blood-derived unfractionated mononuclear cells or CD34(+)CD19(+)CD10(-) cells into immune-deficient mice. In contrast to the in vitro situation, all stages of B-cell differentiation were observed in vivo, including pro-B, pre-B, and slgM(+) B cells. Interestingly, human progenitors with the ability to differentiate along both B-lymphoid and granulocytic pathways were also detected among human CD34(+)CD38(low) cells in the marrow of chimeric mice 6 to 7 weeks after transplantation. Both in vitro and in vivo systems will offer an invaluable tool to further identify the lymphoid and myeloid potentialities of primitive progenitor cells isolated from fetal as well as adult human hematopoietic tissues and characterize stromal-derived signals that regulate their function. (C) 1997 by The American Society of Hematology.